HK Innoen K-Cab, Chile Product Approval... Accelerating Entry into Latin America

HK Innoen's new drug for gastroesophageal reflux disease, K-CAB, has expanded its approved countries to eight, including Korea, by obtaining marketing authorization in Chile.

HK Innoen's gastroesophageal reflux disease treatment Keycap (domestic name K-Cap)
[Photo by HK Innoen]

HK Innoen announced on the 20th that K-CAB (marketed as Ki-CAB in Chile) recently received marketing authorization from the National Institute of Public Health under the Chilean Public Health Ministry. In 2018, HK Innoen signed export contracts with major Latin American pharmaceutical company Laboratorios Carnot for 17 Latin American countries including Chile, Peru, and Mexico. Additionally, for Brazil, the largest market in Latin America, an export contract was signed in 2022 with local pharmaceutical company Europharma, establishing a foothold in a total of 18 Latin American countries. Among these, Mexico and Peru launched the product in May and October of last year respectively, and with the recent approval in Chile, the company is accelerating its expansion into the Latin American market.

K-CAB is a new drug for gastroesophageal reflux disease belonging to the potassium-competitive acid blocker (P-CAB) class. It shows rapid efficacy within 30 minutes after administration and has demonstrated effectiveness and safety even with long-term use up to six months. The Chilean market name, Ki-CAB, has been approved for four indications: ▲treatment of erosive gastroesophageal reflux disease ▲treatment of non-erosive gastroesophageal reflux disease ▲treatment of gastric ulcers ▲and combination antibiotic therapy for Helicobacter pylori eradication in patients with peptic ulcers and chronic atrophic gastritis.

Dalwon Kwak, CEO of HK Innoen, stated, “K-CAB is rapidly securing its position in the P-CAB market by quickly capturing the growing Latin American market,” and added, “With many Latin American countries awaiting approval this year, we expect K-CAB’s overseas market expansion to accelerate even further.”